Belviq Approval History
- FDA approved: Yes (First approved June 27th, 2012)
- Brand name: Belviq
- Generic name: lorcaserin
- Company: Arena Pharmaceuticals, Inc.
- Treatment for: Obesity
Belviq (lorcaserin) is a serotonin 2C receptor agonist indicated for chronic weight management in adults who are obese, or overweight and who have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.
FDA Approval History for Belviq
|Jun 27, 2012|| FDA Approves Belviq to Treat Some Overweight or Obese Adults|
|May 10, 2012||Lorcaserin Receives Positive Vote From FDA Advisory Committee|
|Feb 1, 2012||Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin|
|Jan 10, 2012||FDA Accepts Resubmission of Lorcaserin New Drug Application|
|Jan 4, 2012||Arena Submits Response to FDA Complete Response Letter for Lorcaserin|
|Dec 22, 2010||Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application|
|Oct 25, 2010||FDA Issues Complete Response Letter for Lorcaserin New Drug Application|
|Sep 17, 2010||Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting|
|Sep 15, 2010||Obesity Expert to Speak to FDA in Support of Treatment Options for Obese Patients|
|Aug 6, 2010||FDA Confirms September 16th Advisory Committee Meeting to Review Lorcaserin for Obesity and Weight Management|
|Feb 26, 2010||Arena Pharmaceuticals Receives PDUFA Date for Lorcaserin NDA|
|Feb 24, 2010||Arena Pharmaceuticals Announces FDA Acceptance of Lorcaserin NDA for Filing|
|Dec 22, 2009||Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management|
Belviq (lorcaserin) Consumer Information
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.